Exelbine (vinorelbine) / Savara - LARVOL DELTA

Cemiplimab FDA Approval Application for Recurrent or Metastatic Cervical Cancer Withdrawn (Targeted Oncology) - "'This is a randomized phase 3 trial [conducted] internationally [to evaluate] cemiplimab 350 mg every 3 weeks or investigators choice chemotherapy. And it worked. Immunotherapy is better than physicians choice chemotherapy in the second-line setting. In fact, not only is it better in response rate, it is better in overall survival, with a hazard ratio of 0.69,' said Bradley Monk...in an interview with Targeted Oncology.'"

Interview

2021 ESMO Review | Hematological Malignancies | Leukemia (YouTube) - "From Total Health's 2021 ESMO Virtual Review on October 23-24, 2021, we bring you a session on leukemia treatment updates presented by Dr. Harry Erba...In the session, Erba covers the VIALE-A study; Ven + Gilt; Ivosidenib in IDH1m Relapsed/Refactory AML; IDH1 mutated myeloid malignancies; IDHentify; and more."

Video

Sarah Cannon to present latest cancer research insights at ASCO20 Virtual Meeting (Businesswire) - "Sarah Cannon announced that it will present its latest cancer research insights at the American Society of Clinical Oncology’s (ASCO®) Annual Meeting being held virtually May 29 – 31, 2020. This year, Sarah Cannon’s drug development and research expertise is featured through more than 110 abstracts and presentations, including data from more than 50 phase 1 studies....Jesus Berdeja, MD...is the discussant on the plenary session focused on 'Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone for Initial Therapy of Newly Diagnosed Multiple Myeloma' on Sunday, May 31 from 12-2:30 PM CT. Dr. Berdeja will also highlight data in an oral presentation on 'Update of CARTITUDE-1: A Phase Ib/II Study of JNJ-4528, a B-Cell Maturation Antigen-Directed CAR-T-Cell Therapy, in Relapsed/Refractory Multiple Myeloma.' (Abstract 8505)."

Clinical data • Breast Cancer • Diffuse Large B Cell Lymphoma • Genito-urinary Cancer • Gynecologic Cancers • Hematological Malignancies • Indolent Lymphoma • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Prostate Cancer • Rectal Cancer • Small Cell Lung Cancer • Solid Tumor

Top Abstracts in Locally Advanced NSCLC From ASCO 2021 (Medscape) - "Dr Thomas Stinchcombe...highlights key abstracts in locally advanced non-small cell lung cancer (NSCLC) presented at the 2021 annual meeting of the American Society of Clinical Oncology....Finally, Dr Stinchcombe discusses the IMPACT trial, which looked at adjuvant gefitinib vs cisplatin/vinorelbine in completely resected NSCLC patients with EGFR mutations."

Video

Extracellular vesicle miRNAs and autophagic CTCs: Predictive and prognostic biomarkers in radiotherapy treated NSCLC patients (AACR-RM 2021) - P=NA, N=38; "This study reports for the first time that EV-miRNAs and autophagic CTCs are predictive and prognostic biomarkers in advanced NSCLC patients under concomitant radio- chemotherapy. Their identification could serve as tumor surrogates for a real-time treatment stratification of NSCLC patients and might also benefit new combinatory strategies based on autophagy inhibition or immunotherapy."

Biomarker • Clinical data

A pilot study of vinorelbine safety and pharmacokinetics in patients with varying degrees of liver dysfunction (OpenCME) - Release Date: 2019-Sep-24; Expiration Date: 2021-Sep-24.

Online CME

Treatment options for mNSCLC after progression (OncLive) - "Leora Horn, MD, MSc, FRCPC: So I think we're back to using docetaxel with or without ramucirumab....Mark A. Socinski, MD: No, I do that too, and I just do a day 1 and 8, q21-day, every 21 days schedule, because I give the ramucirumab, but I don't know that there's any clinical trial data using ramucirumab with a weekly dose. Heather A. Wakelee, MD: Right. They're talking about doing a study but it hasn't been done....Mohammad Jahanzeb, MD: Well while they're at doing a study, I hope they choose different cytotoxic agents also....John V. Heymach, MD, PhD: Yeah. You know but in the third-line setting, so I certainly agree that docetaxel is not a perfect drug, and it would be interesting to see different combinations with ramucirumab."

Video